123 related articles for article (PubMed ID: 8082095)
1. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression.
Cohen MK; Arber DA; Coffield KS; Keegan GT; McClintock J; Speights VO
Cancer; 1994 Oct; 74(7):1899-903. PubMed ID: 8082095
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in prostate cancer.
Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
[TBL] [Abstract][Full Text] [Related]
3. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma.
Bostwick DG; Dousa MK; Crawford BG; Wollan PC
Am J Surg Pathol; 1994 Dec; 18(12):1240-6. PubMed ID: 7977947
[TBL] [Abstract][Full Text] [Related]
6. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples.
Speights VO; Cohen MK; Riggs MW; Coffield KS; Keegan G; Arber DA
Br J Urol; 1997 Aug; 80(2):281-6. PubMed ID: 9284203
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
9. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases.
Adlakha H; Bostwick DG
Hum Pathol; 1994 Feb; 25(2):135-9. PubMed ID: 7509774
[TBL] [Abstract][Full Text] [Related]
10. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report.
Ghannoum JE; DeLellis RA; Shin SJ
Int J Surg Pathol; 2004 Apr; 12(2):167-70. PubMed ID: 15173926
[TBL] [Abstract][Full Text] [Related]
11. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
Krupski T; Petroni GR; Frierson HF; Theodorescu JU
Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
13. Paraganglia of the prostate. Location, frequency, and differentiation from prostatic adenocarcinoma.
Ostrowski ML; Wheeler TM
Am J Surg Pathol; 1994 Apr; 18(4):412-20. PubMed ID: 8141432
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
15. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H
Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602
[TBL] [Abstract][Full Text] [Related]
16. Clinical implication of neuroendocrine differentiation in prostatic adenocarcinomas.
Constantinides C; Pavlaki K; Zizi D; Gavriel J; Mitropoulos D; Garifalos J; Dimopoulos C
Urol Int; 1995; 55(3):134-6. PubMed ID: 8540155
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
Abrahamsson PA; Cockett AT; di Sant'Agnese PA
Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
19. Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study.
Weaver MG; Abdul-Karim FW; Srigley J; Bostwick DG; Ro JY; Ayala AG
Am J Surg Pathol; 1992 Jan; 16(1):62-8. PubMed ID: 1370193
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
